2025-11-14 15:52:19
Latest Post
BEL receives orders worth Rs. 871Crore
Rossell Techsys Recognized as Outstanding Supplier by Lockheed Martin
660 MW Unit-1 of SJVN's Buxar Thermal Power Project Successfully achieves Commercial Operation
Adani Cement is the First Indian Cement Company to become a TNFD Adopter
Liberty General Insurance Launches Surety Insurance Business in India
Research
Angel Broking recommends Buy on Dishman Pharmaceuticals with a Target Price of Rs. 123
Posted On : 2014-06-08 20:29:11( TIMEZONE : IST )
For 4QFY2014, Dishman Pharmaceuticals & Chemicals (Dishman) posted results better than our expectations on all fronts. It posted a top-line growth of 15.9% to Rs. 400.6cr V/s an expected Rs. 359cr. The growth was driven by the CRAMS segment, which posted a yoy growth of 24.6% for the quarter. The OPM came in at 21.9% V/s 19.4% in 3QFY2014 and 20.9% in 4QFY2013. This aided the net profit to come in at Rs. 22.6cr (V/s an expected Rs. 17cr), a yoy growth of 21.6%. Currently, we have a Buy rating on the stock with a price target of Rs. 123.
Results better than expected: For 4QFY2014, Dishman posted better-thanexpected results on all fronts. It posted a top-line growth of 15.9% to Rs. 400.6cr V/s an expected Rs. 359cr. The growth was driven by the CRAMS segment, which posted a yoy growth of 24.6%, driven by Carbogen Amcis, which grew by 51.8% yoy, while Indian CRAMS declined by 8.2% yoy. The MM segment on the other hand de-grew by 12.2% yoy. With this, the CRAMS segment contributed 72.2% V/s 63.3% in the corresponding quarter of last year. The OPM came in at 21.9% V/s 19.4% in 3QFY2014 and 20.9% in 4QFY2013. This aided the net profit to come in at Rs. 22.6cr (V/s an expected Rs. 17cr), a yoy growth of 21.6%.
Outlook and valuation: We expect Dishman's net sales and net profit to come in at Rs. 1,662cr and Rs. 178.0cr, respectively, in FY2016. At current levels, Dishman is trading at 4.7x and 4.0x FY2015E and FY2016E earnings, respectively. We believe the current valuations are attractive, hence, we maintain our Buy recommendation on the stock with a price target of Rs. 123.
Shares of DISHMAN PHARMACEUTICALS & CHEMICALS LTD. was last trading in BSE at Rs.104.45 as compared to the previous close of Rs. 104. The total number of shares traded during the day was 436834 in over 7210 trades.
The stock hit an intraday high of Rs. 106.4 and intraday low of 101.5. The net turnover during the day was Rs. 45580099.
